Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients

• Status: Recruiting
• Trial end date: 2023-06-26
• Target enrollment: 0
• Participant gender: All

Summary

Phase 3 study to assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yooyoung Pharmaceutical Co., Ltd.
• Treatments: Dapagliflozin; Metformin

Criteria

Inclusion Criteria:

• Patient who contsent to participate in this tiral by written informed consent form

• A man or woman over 20 years old

• Type 2 Diabetes patients

Exclusion Criteria:

• Patients with severe renal impairment, end-stage renal disease or on dialysis

• Type 1 diabetes patients

• Patients with a history of acute or chronic target acidosis, including lactic acidosis and diabetic ketoacidosis